Kestra Revenue Jumps 52% in Fiscal Q1

Kestra Medical Technologies (NASDAQ:KMTS) reported Q1 FY2026 results, with revenue surging 52% to $19.4 million, driven by a 51% increase in ASSURE wearable defibrillator prescriptions, and gross margin improving 12.8 percentage points to 45.7%. Despite this strong top-line growth and a raised FY2026 revenue outlook to $88 million, the company's net loss widened significantly to $25.8 million as operating expenses sharply increased to $37.7 million, reflecting substantial investments in commercial expansion and infrastructure, leading to continued significant cash burn and a lack of operating leverage.

Analysis

Kestra Medical Technologies (NASDAQ:KMTS) demonstrated robust top-line momentum in its Q1 FY2026 results, but this was overshadowed by escalating costs and widening losses. Revenue surged 52% year-over-year to $19.4 million, directly correlated with a 51% increase in prescriptions for its core ASSURE wearable defibrillator, prompting management to raise full-year revenue guidance to $88 million. Gross margin also showed significant improvement, expanding 12.8 percentage points to 45.7% due to increased volume and a more favorable in-network patient mix. However, this growth required substantial investment, with operating expenses rising sharply to $37.7 million from $22.6 million in the prior-year period. Consequently, the company failed to achieve operating leverage, as the net loss widened to $25.8 million and the adjusted EBITDA loss increased to $19.4 million. The aggressive spending resulted in a significant quarterly cash burn of $36.4 million, reducing cash and equivalents to $201.2 million. While U.S. payer coverage is strong, reaching nearly 90% of the addressable market, the lack of updates on international expansion keeps the company's growth story confined to the domestic market for the near term.

Key Decisions for Investors

• Given the strong 52% revenue growth and raised guidance, growth-focused investors may see the current high-spend phase as a necessary investment for market capture, but should be prepared for continued stock volatility tied to profitability concerns.
• Investors should critically monitor the company's cash burn rate ($36.4 million in Q1) against its remaining cash reserves ($201.2 million), as the current trajectory implies a cash runway of approximately five to six quarters without additional financing or a significant improvement in operating leverage.
• Pay close attention to future reports for evidence that gross profit growth is beginning to outpace the increase in operating expenses, and look for any announcements regarding international regulatory progress, such as a CE Mark, which would be a key catalyst for expanding the total addressable market.